Toronto, Canada
PlantForm Corporation, a Canadian biotechnology firm established in 2008, harnesses a proprietary, plant-based system for the development and production of pharmaceuticals. Its vivoXPRESS® platform stands out by offering cost-effective manufacture of monoclonal antibodies, therapeutic proteins, and vaccines crucial for combating diseases like cancer, HIV/AIDS, and the Ebola virus.
The company's drug pipeline includes three biosimilar cancer treatments, notably a plant-derived version of trastuzumab akin to the breast cancer drug Herceptin®. Additionally, they are developing innovator antibodies for HIV/AIDS, funded by the Government of Canada and the Bill & Melinda Gates Foundation, along with Ebola virus treatments supported by both the National Research Council of Canada Industrial Research Assistance Program (NRC-IRAP) and the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID).
Their last funding round was a $25.00K grant from the Natural Sciences and Engineering Research Council of Canada (NSERC) in February 2018. As PlantForm seeks partnerships to expand its drug portfolio, particularly in biosimilars, it presents an intriguing opportunity for investors eyeing innovation in biopharmaceuticals.
